Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.

Gutiérrez J, Vallejo B, Barbosa H, Pinzón J, Delgado G.

Immunopharmacol Immunotoxicol. 2013 Jun;35(3):321-8. doi: 10.3109/08923973.2013.768635.

PMID:
23473403
2.

Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.

Borborema SE, Schwendener RA, Osso JA Jr, de Andrade HF Jr, do Nascimento N.

Int J Antimicrob Agents. 2011 Oct;38(4):341-7. doi: 10.1016/j.ijantimicag.2011.05.012.

3.

Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.

Moosavi Z, Nakhli A, Rassaii S.

Int J Dermatol. 2005 Dec;44(12):1064-5. No abstract available.

PMID:
16409282
4.

Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.

Kalat SA, Khamesipour A, Bavarsad N, Fallah M, Khashayarmanesh Z, Feizi E, Neghabi K, Abbasi A, Jaafari MR.

Exp Parasitol. 2014 Aug;143:5-10. doi: 10.1016/j.exppara.2014.04.013.

PMID:
24780938
6.

Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.

Vouldoukis I, Rougier S, Dugas B, Pino P, Mazier D, Woehrlé F.

Vet Parasitol. 2006 Jan 30;135(2):137-46.

PMID:
16242844
7.

An experimental approach to studying the effectiveness and safety of meglumine antimoniate formulations.

Delgado G, Sánchez Y, Plaza D, Mariño A, Granados D.

Biomed Pharmacother. 2011 Dec;65(8):569-77. doi: 10.1016/j.biopha.2010.12.016.

PMID:
21733656
8.
9.

Double-walled microspheres loaded with meglumine antimoniate: preparation, characterization and in vitro release study.

Navaei A, Rasoolian M, Momeni A, Emami S, Rafienia M.

Drug Dev Ind Pharm. 2014 Jun;40(6):701-10. doi: 10.3109/03639045.2013.777734.

PMID:
23594302
10.

Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.

Gonzalez-Fajardo L, Fernández OL, McMahon-Pratt D, Saravia NG.

PLoS Negl Trop Dis. 2015 May 29;9(5):e0003820. doi: 10.1371/journal.pntd.0003820.

11.

Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro.

Néris PL, Caldas JP, Rodrigues YK, Amorim FM, Leite JA, Rodrigues-Mascarenhas S, Barbosa-Filho JM, Rodrigues LC, Oliveira MR.

Exp Parasitol. 2013 Oct;135(2):307-13. doi: 10.1016/j.exppara.2013.07.007.

12.

Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.

Shamsi Meymandi S, Javadi A, Dabiri S, Shamsi Meymandi M, Nadji M.

Arch Iran Med. 2011 Jul;14(4):238-43. doi: 0011144/AIM.003.

13.

Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.

Bogenrieder T, Lehn N, Landthaler M, Stolz W.

Dermatology. 2003;206(3):269-72.

PMID:
12673089
14.

Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.

Robledo SM, Valencia AZ, Saravia NG.

J Parasitol. 1999 Apr;85(2):360-6.

PMID:
10219320
15.
16.

Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.

Demicheli C, Ochoa R, da Silva JB, Falcão CA, Rossi-Bergmann B, de Melo AL, Sinisterra RD, Frézard F.

Antimicrob Agents Chemother. 2004 Jan;48(1):100-3.

17.

In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum.

Pujals G, Suñé-Negre JM, Pérez P, García E, Portus M, Tico JR, Miñarro M, Carrió J.

Parasitol Res. 2008 May;102(6):1243-7. doi: 10.1007/s00436-008-0901-z.

PMID:
18278586
18.

American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.

Pimentel MI, Baptista C, Rubin EF, Vasconcellos Ede C, Lyra MR, Salgueiro Mde M, Saheki MN, Rosalino CM, Madeira Mde F, Silva AF, Confort EM, Schubach Ade O.

Rev Soc Bras Med Trop. 2011 Mar-Apr;44(2):254-6.

19.

Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.

Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG.

J Infect Dis. 2006 May 15;193(10):1375-83.

PMID:
16619185
20.

Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major.

Bahrami S, Esmaeilzadeh S, Zarei M, Ahmadi F.

Parasitol Res. 2015 Dec;114(12):4617-24. doi: 10.1007/s00436-015-4707-5.

PMID:
26346452

Supplemental Content

Support Center